Nine patients with onco-hematological malignancies with a poor prognosis due to high risk of relapse received immunotherapy with interleukin-2 (IL-2) and interferon (IFN alpha 2b ) s.c. as maintenance therapy after receiving autologous bone marrow or peripheral blood stem cell transplantation (ABMT/PBSCT). All the patients were considered at very high risk of relapse. We attempted to assess the efficiency, toxicity and clinical effects of these cytokines in these patients. Five patients were treated with high-dose of IL-2 and the other four patients with escalating doses every month. Side-effects in the first group of patients consisted of fever, chills, weakness, nausea, anorexia, loss of weight and local dermatitis in the injection site. Toxicity on the WHO scale was grade II in three patients and grade IV in the other two patients. In the second group of patients, the same clinical signs of toxicity appeared, but these were grade I on the WHO scale in all patients. None of the patients had infections or died in relation to administration of IL-2. Four patients died of relapse or progression of their hematological malignancies. The other five patients are alive, one in chronic phase of CML and the other four patients are in complete remission of their malignancies. Keywords: hematopoietic progenitor transplantation; immunotherapy; toxicity IL-2 is a cytokine secreted by T-helper lymphocytes and is able to stimulate proliferation of T-lymphocytes which carry IL-2 receptors. It also stimulates proliferation of Tlymphocytes with antitumoral activity. This characteristic was described in 1980. It was demonstrated that lymphocytes in the non-stimulated state were able to mediate lysis of tumoral cells but not lysis of normal cells 3 or 4 days later in presence of IL-2.
IL-2 is a cytokine secreted by T-helper lymphocytes and is able to stimulate proliferation of T-lymphocytes which carry IL-2 receptors. It also stimulates proliferation of Tlymphocytes with antitumoral activity. This characteristic was described in 1980. It was demonstrated that lymphocytes in the non-stimulated state were able to mediate lysis of tumoral cells but not lysis of normal cells 3 or 4 days later in presence of IL-2.
1,2 These lymphocytes were called LAK cells.
These characteristics were studied in vitro in some animal tumours, [3] [4] [5] [6] but it was not possible to obtain enough IL-2 of natural origin to study its use and efficiency in humans with disseminated cancer. In 1984 sufficient IL-2 was obtained to begin studies in human beings after identification of the DNA sequence of the gene that codifies synthesis of IL-2. It was possible to express this gene in E. coli. From then on it was used in human beings with disseminated cancer who had no possibilities of therapy. 7, 8 Later some studies were undertaken using different dosages and different approaches to administration. [9] [10] [11] [12] [13] [14] [15] [16] In 1990 the first results of the efficiency and toxicity of IL-2 s.c. and IFN alpha 2b i.m. in metastatic renal cancer were reported. 17, 18 Later in 1991, Ackerstein et al 19 reported that immunotherapy with IL-2 in conjunction with bone marrow transplantation (BMT) in mice increased the graft-versusleukemia (GVL) effect and felt that it should be further investigated as a model for control of minimal residual disease and decreasing the relapse rate after BMT for hematologic malignancies.
Rate of relapse in patients with poor prognostic malignancies after autologous or syngeneic bone marrow transplantation is higher than 50% when no other therapy after BMT is given. For this reason it was hoped to improve this rate with IL-2 and IFN alpha 2b treatment in the period of risk of relapse. [20] [21] [22] The aim of this study was to assess the efficiency, toxicity and clinical effects of immunotherapy with IL-2 and IFN alpha 2b in such patients.
Patients and methods
A total number of nine patients received immunotherapy on an outpatient basis. All of them had previously received an autologous or syngeneic BMT or peripheral blood stem cell transplant (PBSCT).
The first group included five patients with the following diagnosis: one disseminated breast carcinoma with skeletal metastases and bone marrow fibrosis, one mediastinal B cell lymphoma with central nervous system relapse and three acute lymphoblastic leukemias (ALL): one resistant LAL, one in third relapse and one in first complete remission. This patient was initially considered to be of good prognosis (he had only two points in the poor prognosis score based on the Pethema scale) (see Table 1 ). However, he had no response to induction chemotherapy so his initially good prognosis was changed to poor prognosis, as is specified in the protocol.
This first group of patients received courses of treatment Another group included four patients with the following diagnoses: one chronic myeloid leukemia (CML), one Ewing's sarcoma in second relapse after two syngeneic peripheral blood stem cell transplants and two acute lymphoblastic leukemias: one in second complete remission and one in first complete remission with more than three points on the prognosis score. This patient had a poor prognosis at diagnosis due to age, leukocytosis, splenomegaly and immunophenotyping, with a total score of six points on the Pethema scale (see Table 1 ).
Treatment in this second group of patients consisted of IL-2 at a dose of 180 000 UI/m 2 × 5 days per week, the first week of the month, doubling the dose every month until a maximum dose of 4.8 × 10 6 UI/m 2 . They also received IFN 500 000 UI/m 2 /day increasing the dose 500 000 UI/m 2 every week until a maximum dose of 6 × 10 6 UI/m 2 /day. This group of patients completed 2 years of treatment.
Characteristics of the patients included in the study are shown in Table 2 .
All patients except those with breast carcinoma and Ewing's sarcoma, had received autologous BMT while in complete remission.
All patients started immunotherapy with IL-2 + IFN when hematological recovery after ABMT or PBSCT was complete, beginning at 1.5 to 2.5 months after transplantation.
Criteria for inclusion of patients in this study were: (1) Performance status on the ECOG scale less than or equal to 2; (2) WBC of 2000/mm 3 or above; (3) platelets of 50 000/mm 3 or above; (4) Hb of 9 g/dl or above; (5) hemostatic, liver and renal parameters in normal ranges.
Patients received this treatment at home self-administered subcutaneously. They came weekly for blood counts for the first 3 months, and once a month we studied hemostatic, liver and renal parameters. From the fourth month they only did one control every month.
While treatment with IL-2 and IFN alpha 2b was underway, patients diagnosed with lymphoma and acute lymphoblastic leukemia completed their central nervous system prophylaxis with intrathecal chemotherapy.
Results
Five out of nine patients who began immunotherapy are alive: four in complete remission and one in chronic phase of his CML; all have finished treatment.
In the first group, four patients died: three patients with ALL died in relapse at 2.5, 11 and 19 months after ABMT and the patient with disseminated breast carcinoma died of disease progression at 30 months after APBSCT. The patient with mediastinal B cell lymphoma is alive and in complete remission at 82 months after ABMT off treatment.
In the second group, two patients with ALL are alive and in complete remission at 75 and 76 months after ABMT and off treatment. The patient with Ewing's sarcoma is alive and in complete remission at 61 months after APBSCT, and the patient with CML is alive and in chronic phase at 78 months after ABMT and at 96 months from diagnosis, both off all treatment.
Toxicity of treatment
None of the patients had infections or died due to IL-2 administration. Three patients in the first group had fever, chills, bone pain, nausea and weakness, grade II of the WHO scale. In the second group, all patients had fever, chills, weakness and bone pain, grade I of the WHO scale. None of the patients had hypertension, diarrhea, liver toxicity, respiratory distress, arrythmias, capillary leak syndrome, edema or hypoalbuminemia.
In summary, the commonest side-effects in both groups were fever and weakness related to the administration of IL-2. However, none of the patients reached a Karnofsky of under 70%. All patients had contact dermatitis at injection sites.
Toxicity related to immunotherapy according to the WHO grading is shown in Table 2 .
Hematological effects
Eosinophilia appeared in all patients in both groups. One patient in the second group had a severe drop in platelet count which returned to normal when IL-2 was discontinued. None of the patients had any changes in hemostatic parameters. II  II  II  II  III  II  0  2  M  24  NHL  I  II  II  I  I  II  0  3  M  11  ALL  II  I  II  II  II  II  0  4  M  11  ALL  II  II  II  II  II  II  0  5  M  20  ALL  II  II  II  II  II  II  0   1  F  8  CML  I  I  I  I  0  I  0  2  M  19  Ewing's sarcoma  I  I  I  I  0  II  0  3  F  9  ALL  II  I  II  II  0  II  III 
Discussion
This report describes the toxicity and hematological effects of an out-patient treatment program based on administration of IL-2 and IFN alpha after autologous bone marrow or peripheral blood stem cell transplantation. IFN alpha has a direct antiproliferative cytoreductive effect, while IL-2 manifests its antitumor effects through stimulation of T cell-dependent and mostly NK cell-dependent immune reactivity. In a study on lymphoma patients, Nagler et al 23 demonstrated that combined IFN alpha and IL-2 in situations of minimal residual disease (MRD) post-ABSCT reduces relapse rates in comparison to historical controls. These results can be explained by the hypothesis that cytokine-mediated immunotherapy activates cytotoxic activity of the host immune system and mediates an antitumor response which may result in increased survival and disease-free survival.
In our study, all patients were at high risk of relapse after ABMT/ABSCT. Four patients died in relapse of their hematological malignancies while the other five are alive, four of them in complete remission of their malignancies.
Most side-effects related to the IL-2 + IFN alpha administration were fever, chills, weakness, nausea, bone pain and dermatitis in the injection site. Eosinophilia appeared in all patients and just one patient had severe thrombocytopenia.
An increased number of bacterial infections has been widely reported as a side-effect when high doses of IL-2 are administered. This is because these patients have chemotactic deficiencies induced by IL-2. 24, 25 However, in our study no patient developed recurrent or significant infections that could be related to IL-2 administration.
In patients with a high risk of relapse after ABMT, immunotherapy with IL-2 and IFN alpha 2b s.c. can be administered on an outpatient basis with acceptable tolerance. Side-effects resolve when therapy is interrupted. Intravenous IL-2 is reported to have caused death in some cases and should be administered in an intensive care unit.
Although it is necessary to include more patients in the study to enable statistical analysis of groups, our study suggests that this immunotherapy and mode of administration have an acceptable toxicity and should be further investigated to ascertain whether it may reduce the number of relapses in patients with an otherwise very bad prognosis.
